Financial

Business briefs: Amgen and Omnicom Group

Amgen said they will continue to spread out their efforts on two different commercial models: biologics and biosimilars.

Business briefs: Novo Nordisk

Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.

Soriot's status update for AstraZeneca: It's complicated

Soriot's status update for AstraZeneca: It's complicated

By

Sizing up his company amid a dismal annual results presentation, AstraZeneca CEO Pascal Soriot told analysts and investors: "We have become a little bit complicated and in many ways out of this, a bit conservative."

Company news: GSK, Salix

GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013.

Company news: BMS goes over the patent cliff

Sales of Bristol-Myers Squibb's Plavix plunged 96% in the third quarter over the same period last year, contributing mightily to an overall 30% drop in sales of the company's products for the quarter, to $3.7 billion.

Amgen's Prolia, Enbrel get sales overhauls, DTC

Amgen's Prolia, Enbrel get sales overhauls, DTC

Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, the company said in a third quarter results call.

Lilly sales dip 11% as diabetes drugs feel payer pressure

By

Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.

Boehringer: Pradaxa, Tradjenta launches face 'economic headwind'

By

The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze.

Abbott, on track for split, posts strong Q2 numbers

By

Abbott Labs reported strong second quarter sales that, though mitigated by an unfavorable exchange rate, cheered analysts and investors, with muscular growth in Humira sales a high point.

Sanofi braces for patent cliff impact

Sanofi braces for patent cliff impact

By

Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.

J&J sales up, but earnings wiped out by settlements, product liability and recall costs

By

Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.

Prolia, Xgeva fall short of analysts' Q3 sales forecasts

By

Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected.

Company news: Johnson & Johnson, Forest Labs and Berkery Noyes

Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30.

UK PR pitch could portend US acquisitions for AstraZeneca

By

AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.

Which Pfizer brands could stay, go in a sell-off

Which Pfizer brands could stay, go in a sell-off

By

Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.

Merck, GlaxoSmithKline earnings reflect product difficulties

By

Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters